Upload Avatar (500 x 500)
Xi Ming Xu
Medical School
Wuhan University
Hubei
Language: Chinese, English
Liver Cancer
Pathogenesis
Radioresistance
Metastasis
Clinical Treatment
Oncology
Cancer Therapy
Tumor
Immunotherapy
Targeted Therapy
Areas of Focus
- Pathogenesis of liver cancer
- Radioresistance mechanisms in cancer
- Metastasis mechanisms in cancer
- Clinical treatment of liver cancer
Work Experience
- 2006-2007: Attending Physician, Oncology Center, Renmin Hospital of Wuhan University
- 2008-2012: Deputy Chief Physician, Master's Supervisor, Oncology Center, Renmin Hospital of Wuhan University
- 2009-2010: Postdoctoral Fellow in Oncology, University of Georgia, USA
- 2013-2019: Chief Physician, Associate Professor, Master's Supervisor, Department of Oncology III, Renmin Hospital of Wuhan University
- 2020: Chief Physician, Associate Professor, Doctoral Supervisor, Department of Oncology III, Renmin Hospital of Wuhan University
Academic Background & Achievements
- 1995-2000: Bachelor of Clinical Medicine, Xianning Medical College
- 2000-2003: Master of Internal Medicine, Wuhan University
- 2003-2006: PhD in Internal Medicine, Wuhan University
- Hosted multiple national and provincial research projects
- Published over 50 research papers
Publications
- The application of nanoparticles in immunotherapy for hepatocellular carcinoma, Hu X, Zhu H, He X, Chen J, Xiong L, Shen Y, Li J, Xu Y, Chen W, Liu X, Cao D, Xu X*, 2023
- Global microarray profiling identified hsa_circ_0064428 as a potential immune-associated prognosis biomarker for hepatocellular carcinoma, Weng Q, Chen M, Li M, Zheng YF, Shao G, Fan W, Xu XM*, Ji J, 2019
- Immune checkpoint modulators in cancer immunotherapy: Recent advances and combination rationales, Fan L, Li Y, Chen JY, Zheng YF, Xu XM*, 2019
- T cell dysfunction in chronic hepatitis B infection and liver cancer: evidence from transcriptome analysis, Wang YG, Zheng DH, Shi M, Xu XM*, 2019
- MXD3 as an Immunological and Prognostic Factor From Pancancer Analysis, Zhang X, He X, Li Y, Xu Y, Chen W, Liu X, Hu X, Xiong L, Xu X*, 2021
- Comprehensive Analysis of the Immune Infiltrates and PD-L1 of m(6)A RNA Methylation Regulators in Hepatocellular Carcinoma, Xu Y, He X, Deng J, Xiong L, Li Y, Zhang X, Chen W, Liu X, Xu X*, 2021
- Immune-related microRNA signature for predicting prognosis and the immune microenvironment in hepatocellular carcinoma, Li Y, He X, Zhang X, Xu Y, Wu Y, Xu X*, 2021
- RMI2 is a prognostic biomarker and promotes tumor growth in hepatocellular carcinoma, Li Y, He X, Zhang X, Xu Y, Chen W, Liu X, Xu X*, 2021
- Identification of a novel immune prognostic model in gastric cancer, Li Y, He X, Fan L, Zhang X, Xu Y, Xu X*, 2021
Awards
- 2022: First Prize of Hubei Provincial Science and Technology Progress Award
- 2022: Model of Medical Ethics, Wuhan University
- 2014: Third Prize of Scientific and Technological Progress of Hubei Province
